Back to mobile site

H.C. Wainwright Reiterates Buy Rating on Inozyme Pharma Inc. (INZY)

April 11, 2025 6:39 AM EDT Send to a Friend
H.C. Wainwright analyst Edward White reiterated a Buy rating and $16.00 price target on Inozyme Pharma Inc. (NASDAQ: INZY).The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login